<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736527</url>
  </required_header>
  <id_info>
    <org_study_id>808</org_study_id>
    <nct_id>NCT01736527</nct_id>
  </id_info>
  <brief_title>Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation</brief_title>
  <official_title>Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% at 6, 9, 12, and 24 Hours Following a Single Instillation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the levels of loteprednol etabonate (LE) in tear fluid following a single topical
      instillation of LE ophthalmic gel 0.5% formulation to healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tear Fluid Levels</measure>
    <time_frame>6 hours</time_frame>
    <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear Fluid Levels</measure>
    <time_frame>9 hours</time_frame>
    <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear Fluid Levels</measure>
    <time_frame>12 hours</time_frame>
    <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear Fluid Levels</measure>
    <time_frame>24 hours</time_frame>
    <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>LE Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LE Gel</intervention_name>
    <description>Single drop of LE Gel 0.5% administered to the study eye on visit 2</description>
    <arm_group_label>LE Gel</arm_group_label>
    <other_name>Lotemax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be healthy volunteers with physiologically normal anterior segments not
             exhibiting clinically significant biomicroscopy findings.

          -  Subjects must have a best-corrected visual acuity of 20/20 or better in each eye.

          -  Subjects must have no active ocular disease or allergic conjunctivitis.

          -  Subjects must have a Schirmer test (without anesthesia) of â‰¥ 10mm in 5 minutes.

          -  Subjects must not be using any topical ocular medications or systemic medication other
             than acetaminophen.

          -  Male subjects or female subjects who are not of childbearing potential. Female
             subjects are considered to not be of childbearing potential if they are postmenopausal
             for at least 12 months or permanently sterilized (eg, tubal occlusion, hysterectomy,
             bilateral salpingectomy)

        Exclusion Criteria:

          -  Subjects having an intraocular pressure less than 5 mmHg or greater than 22 mmHg or
             any type of glaucoma.

          -  Subjects with a history of ocular trauma, infection, or inflammation within the last 3
             months.

          -  Subjects having any contraindication to the use of, or known sensitivity or allergy
             to, the study drug(s) or their components.

          -  Subjects wearing contact lenses on the day of Visit 2 and/or Visit 3 of the study

          -  Subjects having, at the Investigator's discretion, the presence of any significant
             illness that could be expected to interfere with the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffery Schafer, OD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raphaele Siou Mermet, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Bausch &amp; Lomb Incorporated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bausch &amp; Lomb Research Clinic</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2012</study_first_submitted>
  <study_first_submitted_qc>November 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <results_first_submitted>August 27, 2013</results_first_submitted>
  <results_first_submitted_qc>August 27, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 8, 2013</results_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Single center, open label, single dose study in healthy volunteers. First participant enrolled 01/08/2013, last participant exited: 01/18/2013.</recruitment_details>
      <pre_assignment_details>A total of 17 participants were screened for this study. Of those screened, 12 participants were included to receive treatment; these subjects constituted the Safety population. No participants discontinued from the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>LE Gel</title>
          <description>A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
LE Gel : Single drop of LE Gel 0.5% administered to the study eye on visit 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LE Gel</title>
          <description>A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
LE Gel : Single drop of LE Gel 0.5% administered to the study eye on visit 2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.6" spread="11.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tear Fluid Levels</title>
        <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
        <time_frame>6 hours</time_frame>
        <population>The primary analysis includes all subjects in the safety population with tear samples collected within the corresponding time window.</population>
        <group_list>
          <group group_id="O1">
            <title>LE Gel</title>
            <description>A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
LE Gel : Single drop of LE Gel 0.5% administered to the study eye on visit 2</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Fluid Levels</title>
          <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
          <population>The primary analysis includes all subjects in the safety population with tear samples collected within the corresponding time window.</population>
          <units>Î¼g/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.633" spread="116.0133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tear Fluid Levels</title>
        <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
        <time_frame>9 hours</time_frame>
        <population>The primary analysis includes all subjects in the safety population with tear samples collected within the corresponding time window.</population>
        <group_list>
          <group group_id="O1">
            <title>LE Gel</title>
            <description>A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
LE Gel : Single drop of LE Gel 0.5% administered to the study eye on visit 2</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Fluid Levels</title>
          <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
          <population>The primary analysis includes all subjects in the safety population with tear samples collected within the corresponding time window.</population>
          <units>Î¼g/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.667" spread="18.1625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tear Fluid Levels</title>
        <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
        <time_frame>12 hours</time_frame>
        <population>The primary analysis includes all subjects in the safety population with tear samples collected within the corresponding time window.</population>
        <group_list>
          <group group_id="O1">
            <title>LE Gel</title>
            <description>A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
LE Gel : Single drop of LE Gel 0.5% administered to the study eye on visit 2</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Fluid Levels</title>
          <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
          <population>The primary analysis includes all subjects in the safety population with tear samples collected within the corresponding time window.</population>
          <units>Î¼g/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.877" spread="29.6464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tear Fluid Levels</title>
        <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
        <time_frame>24 hours</time_frame>
        <population>The primary analysis includes all subjects in the safety population with tear samples collected within the corresponding time window.</population>
        <group_list>
          <group group_id="O1">
            <title>LE Gel</title>
            <description>A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
LE Gel : Single drop of LE Gel 0.5% administered to the study eye on visit 2</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Fluid Levels</title>
          <description>Following a single dose of LE gel 0.5% administered into the study eye, tear samples will be collected via a Schirmer strip at 6, 9, 12 and 24 hours following the dose</description>
          <population>The primary analysis includes all subjects in the safety population with tear samples collected within the corresponding time window.</population>
          <units>Î¼g/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.408" spread="3.3631"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <desc>All 12 subjects were exposed to a single dose of LE Gel.</desc>
      <group_list>
        <group group_id="E1">
          <title>LE Gel</title>
          <description>A single dose LE Gel 0.5% administered into the study eye, tear samples collected at 6, 9, 12, and 24 hours after instillation by Schirmer strip to measures levels of LE in tears.
LE Gel : Single drop of LE Gel 0.5% administered to the study eye on visit 2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Non-Ocular Treatment-Emergent Adverse Events Population: Safety</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>All 12 subjects were exposed to a single dose of LE Gel.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>RaphaÃ«le Siou-Mermet, MD, MS</name_or_title>
      <organization>Bausch &amp; Lomb Incorporated</organization>
      <phone>+33160871491</phone>
      <email>raphaele.siou-mermet@bausch.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

